|Bid||19.19 x 1000|
|Ask||19.20 x 3200|
|Day's Range||18.58 - 19.71|
|52 Week Range||2.35 - 21.05|
|Beta (3Y Monthly)||-0.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 3, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.40|
HENDERSON, NV / ACCESSWIRE / October 15, 2018 / A fascinating biotechnology firm PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the between late August and early September going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain of 1795% as of the close on Friday. PPCB may start receiving increased attention from the street at any moment. PPCB has a 52 week high of $0.77.
NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. S&P 500 Index decreased 2.06 percent to close at 2,728.37 and the Nasdaq Composite Index closed down 1.25 percent to close at 7,329.06. The market losses are “a reaction from investors finally realizing we are in a higher interest-rate environment, and given the elevated level of stocks, market participants were likely looking for a reason to sell,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...
Amarin Corporation (AMRN) expects that more than 25% of adults in the United States suffer from cardiovascular risk factors other than cholesterol, such as elevated triglyceride levels and diabetes. According to Amarin’s investor presentation, almost 50 million–70 million adults in the United States have triglyceride levels of higher than 150 mg/dL (milligrams per deciliter) and thus are part of the at-risk patient pool. While a significant portion of these patients are on statin therapy, they require additional treatment in the form of lipid-modifying prescription drugs.
As per Amarin’s (AMRN) investor presentation, the company aims to position Vascepa as a new treatment paradigm in the cardiovascular space. Amarin estimates that 38 million people in the United States are currently being treated with statin therapies mainly to control cholesterol. The best-selling statin therapy, Pfizer’s (PFE) Lipitor, managed to earn almost $12 billion annually before the launch of its generic version.
The rise was mainly attributable to the company’s presentation at the Cantor Global Healthcare Brokers Conference just a few days after it released positive data from its REDUCE-IT study of Vascepa. Amarin has reported a YTD (year-to-date) return of 353.87%. Amarin has emerged as one of the best-performing biotechnology stocks in 2018.
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Major U.S. markets closed up on Wednesday, with the Dow Jones hitting a record high for the 15th time this year on upbeat economic data. However, market gains ...
With a multi-billion dollar market opportunity, companies in the cardiac monitoring arena have been big wins in the public realm. IRhythm (IRTC) shares have gone from $12 to $90 since their IPO a few years ago, as they're growing quickly and addressing a big market with their unique Zio device, which monitors a patient's heartbeat for irregularities remotely. Biotricity (BTCY) is one of the more recent entrants here with their Bioflux cardiac monitor, and they're now planning on a second product called Biopatch that should open up the market even further.
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / If you're an investor looking to make huge gains fast, Biotech and Cannabis stocks provide the best opportunity. Each market has a huge following of investors ...
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Major U.S. markets finished flat on Friday. For the third quarter, the S&P 500 Index jumped over 7 percent, its best quarter since 2013, while the Dow Jones ...
Fish-Oil Heart Medicine Is the Rarest of Drug Breakthroughs — Max NisenWhen medical breakthroughs are announced, they often affect a surprisingly small number of people. Many new drugs these days are targeting rare diseases or niche patient groups, and their impact is further restricted by price.
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Warning! GuruFocus has detected 2 Warning Sign with INTC. The clinical-stage biopharmaceutical company has a market cap of $911 million.
Amarin witnessed a 17% YoY rise in Vascepa product revenues in the second quarter due to a solid rise in prescriptions for the drug and improved productivity across the company. According to the company’s second-quarter conference call, Symphony Health Solutions and IQVIA estimated the rise in normalized Vascepa prescriptions the second quarter of 77,000 and 84,000, respectively, on a YoY basis.
Amarin (AMRN) is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting unmet demand in the cardiovascular space. The company has witnessed a dramatic rise in its share prices from $2.99 on September 21 to $13.45 on September 26 mainly due to the positive top-line results from the REDUCE-IT cardiovascular outcomes study announced on September 24. According to Amarin’s press release, the outcomes study evaluated the potential of VASCEPA in reducing the risk of cardiovascular events in patients with LDL-C levels controlled by statin therapy.